The association of phospholipase (PLD)-1 with protein kinase C-related protein kinases, PKN␣ and PKN␤, was analyzed. PLD1 interacted with PKN␣ and PKN␤ in COS-7 cells transiently transfected with PLD1 and PKN␣ or PKN␤ expression constructs. The interactions between endogenous PLD1 and PKN␣ or PKN␤ were confirmed by co-immunoprecipitation from mammalian cells. In vitro binding studies using the deletion mutants of PLD1 indicated that PKN␣ directly bound to residues 228 -598 of PLD1 and that PKN␤ interacted with residues 1-228 and 228 -598 of PLD1. PKN␣ stimulated the activity of PLD1 in the presence of phosphatidylinositol 4,5-bisphosphate in vitro, whereas PKN␤ had a modest effect on the stimulation of PLD1 activity. The stimulation of PLD1 activity by PKN␣ was slightly enhanced by the addition of arachidonic acid. These results suggest that the PKN family functions as a novel intracellular player of PLD1 signaling pathway.
PKN␣ is a serine/threonine protein kinase whose regulatory domain in the N-terminal region contains three repeats of leucine zipper-like sequences (CZ1-3) and a D region, and whose catalytic domain in the C-terminal region is highly homologous to those of PKC 1 family members (1) . The protein kinase activity is enhanced by fatty acids such as arachidonic acid (2) and the small GTP-binding protein Rho through the direct interaction with the CZ1 region containing the RhoA effector motif class I in a GTP-dependent manner (3) (4) (5) . This protein kinase makes a family that comprises at least three gene products including PKN␣/PRK1, PKN␤, and PRK2 (6, 7) . The CZ1 regions of PKN␤ and PRK2 have the RhoA effector motif class I sequences (8) , and they can interact with RhoA (6, 9 -11). We previously reported that the D region of PKN␣ contains the autoinhibitory domain (12) . It blocks the access of the catalytic domain to the substrate. Arachidonic acid can recover the catalytic activity from this autoinhibition (12) , suggesting that arachidonic acid causes conformational change of PKN␣ to release the autoinhibitory domain. PKN␤ and PRK2 conserve the domains corresponding to the autoinhibitory domain of PKN␣ (6, 12) ; however, they are only slightly activated by arachidonic acid (6, 13) . Therefore, PKN␤ and PRK2 may need some other factors for conformational changes to release their autoinhibitory domains.
PKN␣ is ubiquitously expressed but is enriched in the brain (14) . In neurons, PKN␣ is concentrated in a subset of endoplasmic reticulum as well as late endosomes, multivesicular bodies, Golgi bodies, secretary vesicles, and nuclei (15) . Thus we have identified several binding partners of PKN␣ by employing a two-hybrid screening using the N-terminal regulatory region of PKN␣ as a bait (16 -20) . One of these partners is the centrosome-and Golgi-localized PKN-associated protein (CG-NAP), localized to centrosomes throughout the cell cycle and the Golgi apparatus at interphase (17) . PKN␤ is localized to the Golgi apparatus and nuclei in cells (6) . Thus, there is the possibility that PKN␣ and PKN␤ may play roles in the control of physiological events in the Golgi apparatus and endosomal compartment such as mitotic Golgi fragmentation and intracellular membrane traffic through the interaction with some other molecules.
In the present study, we have focused attention on phospholipase D (PLD)-1 showing overlapping subcellular localization with PKN␣ and PKN␤: endoplasmic reticulum, Golgi apparatus, late endosomes, and plasma membrane (21, 22) . PLD hydrolyzes phosphatidylcholine to generate the signaling lipid phosphatidic acid. Phosphatidic acid has been hypothesized to act as a fusogenic lipid in vesicular transports such as exocytosis and endocytosis. Many cell types express the known PLD1 and/or PLD2 isozymes, which become activated in response to a wide variety of agonists through heterotrimeric G proteincoupled or tyrosine kinase receptors. It has been proposed that the link between receptor stimulation and PLD activation is mediated by PKC, ADP-ribosylation factor, and Rho family members, which have been shown to stimulate PLD1 directly using in vitro reconstitution assays (23) (24) (25) (26) (27) (28) (29) . They can act alone to stimulate PLD1 and in combination to elicit a synergistic activation (26 -28, 30) .
In this report, we show that PLD1 associates with PKCrelated protein kinases, PKN␣ and PKN␤, in vitro and in vivo. Furthermore, we demonstrate that PKN␣ stimulates the PLD1 activity through the direct interaction in vitro. These results suggest that the PKN family participates in the PLD1 signaling pathway.
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Plasmid Construction-The pTB701/HA/hPKN␣ plasmid used to express HA-tagged human PKN␣ in COS-7 cells was constructed by subcloning the EcoRI fragment of pMhPKN-H4 (1) containing the full length of hPKN␣ to the EcoRI site of pTB701/HA (35) . The pTB701/HA/ hPKN␣N and pTB701/HA/hPKN␣CA plasmids were constructed as follows: the cDNA fragment encoding hPKN␣ (residues 1-540) was obtained by digesting phPKNH4 with EcoRI and BamHI; the cDNA fragment encoding hPKN␣ (residues 561-942) was obtained by polymerase chain reaction; and each cDNA fragment was inserted into pTB701/HA. The pTB701/HA/hPKN␤ plasmid was made by inserting the EcoRI fragment of pRc/CMV/hPKN␤ into pTB/701/HA. The pTB701/HA/hPKN␤N and pTB701/HA/hPKN␤CA plasmids for the expression in mammalian cells were made by digesting pRc/CMV/hPKN␤ with EcoNI, filling the ends with T4 polymerase, ligating with EcoRI linker, digesting with EcoRI, and inserting the resulting fragments encoding hPKN␤ (residues 1-520 and 520 -889) into the EcoRI site of pTB701/HA, respectively. The pTB701/FLAG/hPLD1 used to express FLAG-tagged human PLD1 in mammalian cells was constructed as described previously (28) . The pTB701/FLAG/hPLD1N plasmid was constructed by deleting the BglII fragment from pTB701/FLAG/hPLD1. The pTB701/FLAG/hPLD1I plasmid was made by digesting pTB701/ FLAG/hPLD1 with NcoI, filling the ends with T4 polymerase, ligating with BglII linker, digesting with BglII, and inserting the resulting fragment encoding hPLD1 (residues 228 -598) to the BglII site of pTB701/FLAG (35) . The pTB701/FLAG/hPLD1C was constructed by digesting pTB701/FLAG/hPLD1 with NcoI, filling the ends with T4 polymerase, ligating with BglII linker, digesting with BglII, and ligating the resulting fragment encoding hPLD1 (residues 598 -1070) to the BglII site of pTB701/FLAG. The pBlueBacHis/GST/hPKN␣ was made as described (12) . The pAcGHLTC/hPKN␤ plasmid was made by digesting pTB701/HA/hPKN␤ with EcoRI and inserting the resulting fragment into the EcoRI site of pAcGHLTC. The pRSETB/hPLD1N for (His) 6 -tagged hPLD1N (residues 1-228) was constructed as follows: the cDNA fragment encoding the amino acid residues 1-228 of hPLD1 generated by polymerase chain reaction was ligated into the BamHI site of pRSETB. The pRSETB/hPLD1I plasmid used to express (His) 6 tagged hPLD1I (residues 228 -598) was made by digesting pTB701/ FLAG/hPLD1I with BglII, and the resulting fragment was inserted into the BglII site of pRSETB.
Expression and Purification of Recombinant PKN␣ and PKN␤-The recombinant baculovirus was generated as described (12) . The Sf9 cells expressing recombinant protein were lysed for 15 min in buffer A (20 mM Tris/HCl, pH 7.5, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 5 mM MgCl 2 , 150 mM NaCl, and 10 g/ml leupeptin) containing 1% Nonidet P-40 at 4°C. The lysate was then centrifuged at 30,000 ϫ g for 20 min at 4°C, and the resulting supernatant was collected. An appropriate volume of glutathione-Sepharose 4B was added to the supernatant, and the mixture was rotated for 1 h at 4°C. After washing with buffer A, the bound proteins were eluted with elution buffer (50 mM Tris/HCl, pH 8.0, 1 mM EDTA, 1 mM dithiothreitol, 1 g/ml leupeptin, and 10 mM reduced glutathione).
Cell Culture-COS-7 and HeLa cells were maintained in Dulbecco's modified Eagle's medium with 10% fetal calf serum. U937 cells were grown in RPMI 1640 medium supplemented with 10% fetal calf serum. The cells were incubated at 37°C in a humidified atmosphere of 5% CO 2 . Transfection to COS-7 cells by electroporation was performed as described (6) .
Immunoprecipitation-Cells were lysed with buffer A containing 1% Nonidet P-40 at 4°C, and the resulting lysate was centrifuged at 10,000 ϫ g for 10 min. The supernatants were incubated with the indicated antibodies at 4°C for 2 h and with protein A-Sepharose for 1 h. The resulting immunoprecipitates were subjected to PLD assay, SDS-polyacrylamide gel electrophoresis, and immunoblot analysis with the indicated antibodies.
In Vitro Binding Assay-Two g of the indicated protein was incubated at 4°C for 2 h with 2 g of either (His) 6 -tagged hPLD1N (residues 1-228) or hPLD1I (residues 228 -598) and then precipitated with glutathione-Sepharose 4B beads. The (His) 6 -tagged hPLD1 fragment that was co-precipitated with the indicated GST-fused proteins was detected by immunoblotting with an anti-(His) 6 antibody.
In Vitro PLD Assay-The immunoprecipitate with anti-FLAG from COS-7 cells expressing FLAG-tagged hPLD1 was reconstituted with the purified proteins in the presence of phosphatidylethanolamine/ phosphatidylinositol 4,5-bisphosphate/[choline-methyl- [ 3 H]dipalmitoylphosphatidylcholine vesicles in a molar ratio of 16:1.4:1 (36) . The mixture was incubated in 20 mM Hepes, pH 7.5, 3 mM EGTA, 80 mM KCl, 2.5 mM MgCl 2 , 2 mM CaCl 2 , and 1 mM dithiothreitol with or without 40 M arachidonic acid, and then the production of [ 3 H]choline was determined (37) . The incubation time was 30 min at 37°C. formed the immunoprecipitation with the anti-FLAG antibody using the lysate of COS-7 cells expressing FLAG-tagged PLD1 and either HA-tagged PKN␣ or PKN␤. The interaction was analyzed by Western blotting with an anti-HA antibody. As shown in Fig. 1 , both PKN␣ and PKN␤ were clearly co-immunoprecipitated with FLAG-tagged PLD1.
RESULTS

Association of PKN␣ and PKN␤ with PLD1-To
To define the association between endogenous PLD1 and PKN␣ or PKN␤ in mammalian cells, we next carried out the immunoprecipitation experiments using the specific antibodies. As shown in Fig. 2B , endogenous PKN␤ was clearly coimmunoprecipitated with endogenous PLD1 from HeLa cells. Fig. 2A shows that PLD1 also interacted with PKN␣ in U937 cells, although the interaction with PKN␣ was weaker than that with PKN␤. These data suggest that the association of PKN␣ and PKN␤ with PLD1 is physiological.
To identify the interaction site(s) of PKN␣ or PKN␤ with PLD1, we made the deletion mutants of PKN␣ and PKN␤ as shown in Fig. 3A . FLAG-tagged PLD1 was co-expressed with HA-tagged PKN␣N (residues 1-540), HA-tagged PKN␣CA (residues 561-942), HA-tagged PKN␤N (residues 1-520), or HAtagged PKN␤CA (residues 520 -889) in COS-7 cells. The cell lysate was subjected to immunoprecipitation with the anti-FLAG antibody, and the interaction was analyzed by Western blotting with the anti-HA antibody. As shown in Fig. 3B , right, PKN␤ clearly bound to PLD1 at the N-and C-terminal regions. PKN␣ also associated with PLD1 at both N-and C-terminal regions (Fig. 3B, left) .
Next, we analyzed the interaction site(s) of PLD1 with PKN␣ or PKN␤. The lysate from COS-7 cells co-expressing either HA-tagged PKN␣ or PKN␤ and three different deletion mutants of FLAG-tagged PLD1 (Fig. 4A) was immunoprecipitated with the anti-FLAG antibody and analyzed by Western blotting with the anti-HA antibody. Fig. 4B shows that both PKN␣ and PKN␤ associated with the PLD1 (residues 1-228) containing phox domain and PLD1 (residues 228 -598) containing pleckstrin homology-like domain, conserved regions I and II, and a part of the loop domain of PLD1 (31) (32) (33) (34) .
Direct Interaction PKN␣ and PKN␤ with PLD1-To investigate whether PKN␣ and PKN␤ directly bind to PLD1, we performed an in vitro binding analysis using the purified proteins. (His) 6 -PLD1N (residues 1-228) and (His) 6 -PLD1I (residues 228 -598) were bacterially expressed and purified as described (17) . The PKN␣ or PKN␤ fused to GST was expressed and affinity-purified from Sf9 cells. The proteins were mixed, and each GST-fusion protein was pulled down by glutathioneSepharose beads. The bound proteins were detected by Western blotting with the anti-(His) 6 antibody. Fig. 5 shows that GST-PKN␤ pulled down both (His) 6 -PLD1N and (His) 6 -PLD1I. On the other hand, GST-PKN␣ associated with (His) 6 -PLD1I, but not with (His) 6 -PLD1N. GST itself did not interact with (His) 6 -PLD1N or (His) 6 -PLD1I. In the co-immunoprecipitation study, PKN␣ associated with both PLD1N and PLD1I in COS-7 cells, suggesting that the interaction of PKN␣ with PLD1 (residues 1-228) in COS-7 cells is mediated by some other molecules.
Stimulation of PLD1 by PKN␣ in Vitro-Because the activators for PLD1 such as PKC and RhoA stimulate the activity of PLD1 through direct interaction, we investigated whether PKN␣ and PKN␤ can stimulate PLD1. FLAG-tagged PLD1 expressed in COS7 cells was immunoprecipitated with the anti-FLAG antibody and was used for this assay. Fig. 6 shows that PKN␣ stimulated the activity of PLD1 in the presence of phosphatidylinositol 4,5-bisphosphate, whereas PKN␤ had a modest effect on the stimulation of PLD1 activity. The PLD1 stimulation by PKN␣ was slightly enhanced by the addition of arachidonic acid, which is a potential activator of PKN␣. This stimulation was independent of ATP (data not shown).
DISCUSSION
In the present study, we demonstrated that the members of the PKN family, PKN␣ and PKN␤, associated with PLD1 and that PKN␣ stimulated PLD1 activity in vitro. This stimulation was ATP-independent, suggesting that it is mediated by direct binding rather than phosphorylation of PLD1. The interaction of PKN␣ with PLD1 was weaker than PKN␤ (Figs. 2 and 3) . Nevertheless, PKN␣ stimulated PLD1 activity to a greater FIG. 5 . In vitro interactions of the N-terminal and internal fragments of PLD1 with PKN␣ and PKN␤. GST-fused PKN␣, PKN␤, and GST were expressed in Sf9 cells and affinity-purified with glutathione-Sepharose beads. (His) 6 -PLD1N and PLD1I expressed and purified from Escherichia coli were incubated with GST-PKN␣ (␣) or GST-PKN␤ (␤). Each GST-fused protein was precipitated as described under "Experimental Procedures." As a control, GST was used instead of these protein kinases (GST). The amounts of (His) 6 -PLD1N (left) or PLD1I (right) co-precipitated with GST-fused proteins were detected by immunoblotting with the anti-(His) 6 antibody. extent than PKN␤ (Fig. 6 ). There may be at least two possible explanations for the lower stimulatory effect of PKN␤. First, the binding nature of PKN␤ with PLD1 was somewhat different from that of PKN␣. PKN␤ directly interacted with the N-terminal (residues 1-228) as well as the internal (residues 228 -598) region of PLD1 (Fig. 5) , whereas PKN␣ interacted directly with the internal region (Fig. 5) and indirectly with the N-terminal region (Fig. 4) . Although PKN␣ and PKN␤ are closely related, this difference in the binding may reflect the distinct effects of these proteins on PLD1 activity. Second, insect cell-expressed PKN␤ used in the PLD1 assay (Fig. 6) was relatively unstable and susceptible to proteolysis (data not shown). Because endogenous PKN␤ in mammalian cells is distributed in membrane and nuclear fractions (6), PKN␤ may need some lipids or binding proteins to form a stable structure. This instability of the enzyme may lower the effect on the PLD1 activity measured in vitro. Further, in the case of RhoA, lipid modification such as geranylgeranylation greatly enhance the stimulatory effect on PLD1 but does not affect the binding (38) , suggesting that RhoA-lipid interaction may help to induce catalytically active conformation of PLD1. Similarly, some conformational change of PKN␤ by association with lipids (or other proteins) might be required to achieve effective stimulation of PLD1. We observed that endogenous PLD activity in COS-7 cells was significantly enhanced by the expression of PKN␤ (data not shown), suggesting that PKN␤ may work as an effective stimulator in vivo.
PKC␣ is well known to stimulate PLD1 activity by direct interaction in a phosphorylation-independent manner. The interaction and the stimulation are enhanced by the presence of phorbol ester (25, (27) (28) (29) , indicating the importance of the conformational change of PKC␣ induced by phorbol ester binding as well as intracellular translocation of PKC␣ to the membrane. Proteolysis studies indicate that the N-terminal regulatory region of PKC␣ mediates this stimulation (25) . The mechanism of PLD1 stimulation by the PKN family presented here seems to be similar to that by PKC␣. However, we observed stimulatory effects with the C-terminal catalytic region of PKN␣ but not with the N-terminal regulatory region (data not shown). Further analyses will be needed to clarify the difference in the mechanism of PLD stimulation between the PKN and PKC families.
PKN␣ and PKN␤ associated with PLD1 through the N-and C-terminal regions (Fig. 3) . We have reported that the Nterminal region of PKN␣ directly interacts with the C-terminal catalytic region and that this interaction inhibits its catalytic activity (39) . Thus, the PLD1 stimulation by the C-terminal region of PKN␣ may be affected by the interaction between its N-terminal region and PLD1. PLD1 stimulation by PKN␣ was enhanced by the presence of arachidonic acid, which is a potential activator of PKN␣ (Fig. 6) . Arachidonic acid activates PKN␣ probably by inducing conformational change to release the N-terminal region and the autoinhibitory region from the catalytic region (12) . This conformational change may help the associated PLD1 to form active conformation. Although PKN␤ has the conserved domain corresponding to the autoinhibitory domain of PKN␣, arachidonic acid has little effect on the protein kinase activity (6) and PLD1 stimulation by this enzyme (Fig. 6, right) , suggesting that conformation of PKN␤ is not sufficiently changed by arachidonic acid.
PKN family proteins interact with the Rho family small GTPase (3) (4) (5) . PKN␣ is activated by the binding of RhoA to its leucine zipper-like domain in a GTP-dependent manner, suggesting that the interaction with GTP-bound RhoA also causes the conformational change of PKN␣ to expose the catalytic domain to substrate. Thus, RhoA might stimulate PLD1 activity by activating the PKN family in addition to the direct interaction with PLD1.
In summary, the PKN family protein kinases modulate the activity of PLD1 by direct protein-protein interaction. Further analysis including the relationship between other cofactors activating PLD1 and the PKN family will provide important insights into the physiological role of PLD1 and PKN family.
